期刊文献+

283例胰腺癌根治术后患者临床资料和生存分析 被引量:8

Survival analysis of 283 cases of pancreatic ductal adenocarcinoma with radical surgery
暂未订购
导出
摘要 目的探讨胰腺癌根治术后患者临床病理特征与预后的关系。方法回顾性分析行胰腺癌根治手术治疗的、病理确诊为胰腺导管腺癌的患者283例,分析其临床病理特征及生存情况。结果 283例患者的中位无瘤生存期(median disease free survival,m DFS)为7.9月,中位总生存期(median overall survival,m OS)为15.0月。多因素分析显示,肿瘤手术切缘状态以及肿瘤TNM分期是影响胰腺癌根治术后患者DFS的独立预后因素(均P<0.05),肿瘤淋巴结状态以及肿瘤TNM分期是影响胰腺癌根治术后患者OS的独立预后因素(均P<0.05)。结论对于胰腺癌根治术后患者,手术切缘状态和TNM分期是影响DFS的独立风险因素,TNM分期和肿瘤淋巴结状态是影响OS的独立风险因素。 Objective To investigate the relationship between the clinicopathological features and prognosis of pancreatic cancer patients after radical surgery. Methods All patients pathologically diagnosed as pancreatic ductal adenocarcinoma( PDA) and receiving radical surgery were retrospectively analyzed. Their clinicopathological and survival data were examined. Results In two-hundred-and-eighty-three PDA patients with radical operation,the median disease-free survival( m DFS) was 7. 9 months,and the median overall survial( m OS) was 15. 0 months. Multi-variate analysis determined surgical margin and TNM stage as independent risk factors for DFS( P〈 0. 05). Lymph node status and TNM stage are independent risk factors for OS( P〈 0. 05). Conclusion For PDA patients treated with radical surgery,surgical margin and TNM stage are independent risk factors for DFS,while TNM stage and lymph node status are independent risk factors for OS.
作者 苏丹 白莉 Su Dan Bai Li(Oncology Department, Zhejiang Provincial People's Hospital, Hangzhou, 310014, China Oncology Department,PLA General Hospital, Beijing, 100853, China)
出处 《实用肿瘤杂志》 CAS 2016年第6期526-530,共5页 Journal of Practical Oncology
关键词 胰腺肿瘤 外科学 预后 pancreas neoplasm surgery prognosis
  • 相关文献

参考文献3

二级参考文献31

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011,61(2) :69 -90.
  • 2郑莹.2010上海市恶性肿瘤报告[R].2010上海市恶性肿瘤报告,2011.
  • 3Group GTS. Treatment of locally unresectable carcinoma of the pancreas : comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone [J]. J Natl Cancer Inst, 1998, 80:751 -755.
  • 4Klaassen DJ, MacIntyre JM, Catton GE,et al. Treatment of locally unresectable cancer of the stomach and pancreas : a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5- fluorouracil-an Eastern Cooperative Oncology Group Study [J]. J Clin Oncol, 1985, 3:373 -378.
  • 5Loehrer P, Powell M, Cardenes H, et al. A randomized phase Ⅲ study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: FA201. J Clin Oncol, 2008, 26(Suppl):214s, abstract 4506.
  • 6Chauffert B, Mornex F, Bonnetain F,et al. Phase lU trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemeitabine alone for locally advanced unresectable pancreatic cancer. De finitive results of the 2000-01 FFCD/SFRO study [J]. Ann Oncol, 2008, 19 : 1592 - 1599.
  • 7Huguet F, Andre T, Hammel P, et al. Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase Ⅱ and Ⅲ Studies [J]. J Clin Oncol, 2007, 25(3) :326 -331.
  • 8Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [ J ]. J Clin Oneol, 1997, 15 (6) :2403 - 2413.
  • 9Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer [ J ]. J Clin Oncol, 2007, 25 (18) :2607 - 2615.
  • 10Von Hoff DD, Ramanathan RK, Borad M J, et al. Gemcitabine plusnab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase Ⅰ/Ⅱ Trial [J]. J Clin Oncol, 2011,29(34):4548 - 4554.

共引文献348

同被引文献62

引证文献8

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部